- Case Report
- Open Access
Primary small intestine mesenteric low-grade fibromyxoid sarcoma with foci of atypical epithelioid whorls and diffuse DOG1 expression: a case report
Diagnostic Pathology volume 15, Article number: 23 (2020)
Low-grade fibromyxoid sarcoma (LGFMS) is a rare fibroblastic tumor often involving deep tissue of trunk and lower extremities in young to middle-aged patients. Rarely, LGFMS can occur in other sites including head and neck, chest, abdomen and female reproductive system. Three cases of LGFMS in mesentery of small intestine have been reported and all have conventional histologic features. Herein we reported a unique case of LGFMS in mesentery of small intestine.
A 43 year-old male with chief complaint of lower back pain for 4 years presented to our hospital. Physical exam reveal a firm, non-tender, non-distended, mobile large abdominal mass, which was shown on abdominal CT as a 10 cm retroperitoneal tumor. Biopsy revealed a spindle cell neoplasm in a myxoid background with a delicate vascular network. Tumor resection was performed. Gross examination of the resected specimen showed a 10.8 cm, tan-white, smooth, firm, lobulated mesenteric mass with bulging and gelatinous cut surface and confined within small bowel serosa. Microscopic examination demonstrated foci epithelioid cords and whorls with prominent atypia, in additional of regular, bland-appearing spindle cells in a fibrous and myxoid stroma and osseous metaplasia. The tumor cells stained diffusely positive for DOG1 with moderate staining density, and diffusely and strongly positive for MUC4. Rearrangement involving FUS (16p11.2) gene was identified with break-apart probe and confirmed by Anchored Multiplex PCR. A final diagnosis of low-grade fibromyxoid sarcoma was rendered.
Our case highlights the importance of including LGFMS in the differential diagnosis of mesenteric tumors and the DOG1 positivity which could represent a potential diagnostic pitfall.
Low-grade fibromyxoid sarcoma (LGFMS), also as known as Evans’ tumor, is a rare fibroblastic tumor. It was first described by Evans in 1987 . The tumor most often involves deep tissue of trunk and lower extremities, especially thigh, in young to middle-aged adults with male predominance in all age groups . Less frequently, LGFMS can occur in abdomen (mesentery, intestine) [3,4,5,6,7] and other sites such as female reproductive system (breast, vagina, vulva, broad ligament) [8,9,10,11,12].
LGFMS is an aggressive low-grade tumor typically composed of deceivingly bland spindle-shaped fibroblast cells residing in variably fibrous/myxoid stroma. The tumor usually grow slowly with infiltration with a propensity for late metastatic potential. The tumor cells have palely eosinophilic cytoplasm and round to ovoid nuclei. Pleomorphic Nuclei, nucleoli and mitotic figures are usually absent .
LGFMS can display some variable, focal morphologic features in addition to conventional alternating areas of giant rosettes and hypercellularity. These features include epithelioid morphology, hyalinization, cyst degeneration, calcification/osseous metaplasia, multinucleated giant cells, nuclear palisading, nuclear pleomorphism, and tumor necrosis [14,15,16,17]. These histologic variations can be misleading. Especially, the giant rosettes featuring central accumulation of collagen and peripheral palisading epithelioid fibroblastic cells can mimic sclerosing epithelioid fibrosarcoma (SEF). Morphologically, SEF differs from LGFMS in two aspects. First, the tumor cells of SEF are epithelioid cells with clear or eosinophilic cytoplasm, forming nests and cords. Second, the stroma is densely sclerotic. SEF is more aggressive than LGMFS in that local recurrences and distant metastases are seen in more than half of cases .
MUC4 is a nearly 100% sensitive and specific marker for LGFMS . Notably, MUC4 expression can also be seen in SEF, synovial sarcomas, ossifying fibromyxoid tumors, epithelioid gastrointestinal stromal tumors and myoepithelial carcinomas [14, 19]. LGFMS can also demonstrate positivity of CD99 and BCL-2 . Interestingly, about 40% of LGFMS cases display patchy expression of DOG1 (discovered on GIST-1) with variable intensity; however, no extensive strong positivity has been ever observed.
Cytogenetically, more than 90% of LGFMS harbor t (7;16)(q34;p11), resulting in FUS-CREB3L2 fusion [20,21,22]. Alternatively, t (11;16)(p11;p11) translocation resulting in EWSR1-CREB3L1 is seen in less than 10% of cases [23, 24]. Of note, MUC4-negative LGFMS with FUS-CREB3L2 fusion has been described .
Pathology of small intestine mesenteric LGMFS have been described in 3 cases from 3 different case reports in English literature. The results reveal conventional histopathologic features of all these 3 cases [3, 26, 27]. All showed conventional morphology, no DOG1 expression, nor epithelioid cells.
Herein we reported a case of LGMFS arising in small intestine mesentery with unconventional epithelioid cords and whorls and extensive, diffuse positivity for DOG-1. Our case highlight the diagnostic challenges of such occurrence.
A 43 year-old male who presented with lower back pain for 4 years, loss of 40 pounds in 17 months and urinary urgency for one month. His past medical history was significant for Bell’s palsy, hyperlipidemia, osteoarthritis of cervical spine and vertigo. Physical exam results were normal except a firm, non-tender, mobile large mass palpated in right side of abdomen. The mass was nondistended. Abdominal CT showed a 10 cm retroperitoneal mass (Fig. 1). Laboratory results showed normal hematologic, biochemical and coagulatory results.
Biopsy revealed a spindle cell neoplasm in a myxoid background with a delicate vascular network. The tumor cells showed small oval nuclei with some cytological atypia including hyperchromatism and angulate nuclei. No mitotic figures nor necrosis was noted. Immunohistochemical studies demonstrated that negativity of SMA, desmin, β-catenin, S100, SOX10, AE1/3, EMA, CD117 and CD34 in the tumor cells. DOG1 stain showed rare nonspecific staining in the tumor cells. Proliferative index was low (< 5%) on ki-67 stain (Data not shown). Further molecular classification was attempted but hindered due to the limited specimen.
Tumor resection was performed with the entire tumor removed. At intraoperative examination, retroperitoneal mass was found clearly intimate with the mesentery and adjacent small bowel showed that the. Gross examination of the resected specimen showed an intact 10.8 × 9.0 × 8.3 cm, tan-white, smooth, firm, lobulated mesenteric mass, which was completely confined within small bowel serosa and had bulging and gelatinous cut surface. The mass was predominately solid (90%) and focally cystic (10%) with a 2.0 × 1.2 × 1.0 cm calcified area (Fig. 2).
Microscopic examination confirmed multinodular and infiltrative pattern (Fig. 3A, B). The majority of the tumor was consisted of regular, bland-appearing spindle cells in a fibrous and myxoid stroma (Fig. 3C, D). Thin walled elongated vessels were noted with areas of hyalinization. In certain areas the tumor cells assumed epithelioid morphology and formed a more cord-like and even whorls with more prominent cytological atypia, which is unusual for LGMFS (Fig. 3E-3J). Perivascular hypercellular areas and osseous metaplasia were present (Fig. 3K, L). Yet, no significant atypia, necrosis nor increased mitotic activity was observed.
Immunohistochemically, the tumor cells lacked of reactivity with CD34; CK5/6, EMA, SOX10, S100, desmin, SMA, MDM2 and GFAP. CD117 stain highlighted rare tumor cells. DOG1 stain showed moderate dense immunoreactivity, while MUC4 immunostain demonstrated diffuse and strong positivity in the tumor cell cytoplasm (Fig. 4).
Rearrangement involving FUS (16p11.2) gene was identified with break-apart probe, while rearrangement of the MDM2 and DDIT3 gene regions was not present, excluding dedifferentiated and myxoid liposarcoma. Additional confirmatory RNA from formalin fixed paraffin embedded tissue was extracted, and targeted RNA sequencing using a customized FusionPlex 86 genes panel (Archer, Boulder, CO)  was performed to reveal a confirmatory FUS-CREB3L2 fusion (Fig. 5).
A final diagnosis of low-grade fibromyxoid sarcoma was made based on the morphologic, immunohistochemical and cytogenetic features of the tumor.
In summary, we identified a rare case of low-grade myxofibrous sarcoma arising in small intestine mesentery. The tumor cells focally formed unusual epithelioid cords/whorls which contained prominent atypical neoplastic cells.
Since LGFMS is a rare tumor that can occur in a wide range of anatomical sites, it should be included in the differential diagnoses of any spindle cell tumor with low cell density. Due to its nature of hypocellularity, fine needle aspiration (FNA) biopsy can yield suboptimal amount of tissue, which may not be adequate for a complete workup to arrive at a definite diagnosis. For the present case, the deep, retroperitoneal location created extra risk of visceral organ injury and additional difficulty in obtaining enough material for further molecular and cytogenetic profiling.
The major differential diagnoses of LGFMS are mesenchymal tumors with fibromyxoid features, such as myxoma, low-grade myxofibrosarcoma, desmoid fibromatosis, nodular fasciitis, perineurioma, neurofibroma, schwannoma, ossifying fibromyxoid tumor, and dermatofibrosarcoma protuberans [13, 29]. These tumors have similar morphologic characteristics include spindle tumor cells and fibromyxoid stroma. The present case had two additional, rare but distinct, morphologic features: (1) focal metaplastic bone, and (2) foci of whorls and cord-like structures of atypical epitheloid cells. The present of bony tissue in the tumor raises the possibility of ossifying fibromyxoid tumor (OFMT), as some OFMTs can be at least focally positive for MUC4 expression. Immunostain with S100, EAAT4, INI1, MUC4 and FISH or PCR for FUS-CREB3L2 or EWSR1-CREB3L1 fusion can make the distinction, as OFMT is immunohistochemically positive for S100 AND EAATA, but negative for INI1, MUC4. It does not harbor t (7;16)(q34;p11) or t (11;16)(p11;p11) either .
The epithelioid foci in the present case can easily cause confusion with extraskeletal myxoid chondrosarcoma (EMCS), especially when bony tissue is present. EMCS is a biphasic neoplasm with cartilaginous foci interspersed with spindle mesenchymal cells. The tumor cells are immunostain positive for INSM1, SOX9, CD99 and S100, but negative for MUC4. They carry rearrangement of the NR4A3 but lack translocations of t (7;16)(q34;p11) or t (11;16)(p11;p11) [31, 32]. SEF, a variant of LGFMS with worse prognosis should also be taken into consideration for differential. SEF usually has large areas of hyalinized fibrous stroma and stains positive for EMA and S100 [14, 24, 33]. Synovial sarcoma (SS) can have epitheloid tumor cells as well. The tumor cells in SS are more uniform and retain t(x;18) translocation .
Another pitfall in the present case is gastrointestinal stromal tumours (GISTs) for three reasons. First, both of these two entities can occur in abdomen. Second, they display similar, and sometimes identical, histologic features or morphologic spectrum. Lastly, they can both show expression of DOG1 (discovered on GIST1). These similarities in location, morphology and immunophenotype can cause considerable diagnostic confusion among pathologists. Although DOG1 is a sensitive and specific marker for GIST, its expression is reported in up to 94.7% of LGFMS. More specifically, nearly 40% cases of abdomen or retroperitoneum LGFMS have variable staining positivity of DOG1 [35,36,37]. It should be emphasized that the differential diagnosis between these two entities relies largely on appropriate molecular profiling: LGFMS expresses MUC4 protein and harbors characteristic gene fusions. In contrast, GISTs show expression of CD117 and CD34 and are associated with Kit or PDGFRA mutations . A combination of cytogenetic analysis of gene fusion and immunohistochemical staining of MUC4, CD117 and CD34 will aid in correct diagnosis.
To the best of our knowledge, our present case is the first of its kind given foci of epitheloid core and whorls and diffusely expressing DOG1. Our findings highlight the need for additional immunohistochemical and molecular studies when faced with such tumors. They also underline the importance of including LGFMS in the differential diagnosis of myxoid spindle and epithelioid DOG1+ tumors in the GI tract.
Availability of data and materials
The data and materials are available upon request.
Discovered on GIST-1
Extraskeletal myxoid chondrosarcoma
Fine needle aspiration
Gastrointestinal stromal tumours
Low-grade fibromyxoid sarcoma
Ossifying fibromyxoid tumor
Sclerosing epithelioid fibrosarcoma
Evans HL. Low-grade fibromyxoid sarcoma. A report of two metastasizing neoplasms having a deceptively benign appearance. Am J Clin Pathol. 1987;88(5):615–9.
Mertens F, Fletcher CD, Antonescu CR, et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Investig. 2005;85(3):408–15.
Geramizadeh B, Zare Z, Dehghanian AR, Bolandparvaz S, Marzban M. Huge mesenteric low-grade fibromyxoid sarcoma: a case report and review of the literature. Rare Tumors. 2018;10:2036361318777031.
Mendoza AS, O'Leary MP, Peng SK, Petrie BA, Li AI, French SW. Low-grade fibromyxoid sarcoma of the sigmoid colon. Exp Mol Pathol. 2015;98(2):300–3.
Kim M, Song TJ, Kang SD, et al. A case of low-grade fibromyxoid sarcoma of the colon. Korean J Gastroenterol. 2014;64(6):375–9.
Kim KJ, Seo JW. Intra-abdominal low-grade fibromyxoid sarcoma of the transverse mesocolon mimicking lymphoma. Jpn J Radiol. 2014;32(6):360–4.
Park IJ, Kim HC, Yu CS, Kim JS, Jang SJ, Kim JC. Low-grade fibromyxoid sarcoma of the colon. Dig Liver Dis. 2007;39(3):274–7.
Kosemehmetoglu K, Ozogul E, Babaoglu B, Tezel GG, Gedikoglu G. Programmed death ligand 1 (PD-L1) expression in malignant Mesenchymal tumors. Turk Patoloji Derg. 2017;1(1):192–7.
Guducu N, Coban I, Bassullu N, Gonenc G, Aydinli K. Low-grade fibromyxoid sarcoma of the vagina: a tumor, not previously reported at this site. Turk J Obstet Gynecol. 2014;11(3):196–7.
VanSandt AM, Bronson J, Leclair C, Mansoor A, Goetsch M. Low-grade fibromyxoid sarcoma of the vulva: a case report. J Low Genit Tract Dis. 2013;17(1):79–81.
Barnhill D, Ismailjee M, Goss N, Ruiz B, Young A. Low-grade fibromyxoid sarcoma of the vulva. J La State Med Soc. 2012;164(2):95–6.
Fras AP, Frkovic-Grazio S. Hyalinizing spindle cell tumor with giant rosettes of the broad ligament. Gynecol Oncol. 2001;83(2):405–8.
Mohamed M, Fisher C, Thway K. Low-grade fibromyxoid sarcoma: clinical, morphologic and genetic features. Ann Diagn Pathol. 2017;28:60–7.
Doyle LA, Wang WL, Dal Cin P, et al. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. Am J Surg Pathol. 2012;36(10):1444–51.
Hisaoka M, Matsuyama A, Aoki T, Sakamoto A, Yokoyama K. Low-grade fibromyxoid sarcoma with prominent giant rosettes and heterotopic ossification. Pathol Res Pract. 2012;208(9):557–60.
Merchant SH. Low grade fibromyxoid sarcoma: report of a case with epithelioid cell morphology, masquerading as a papillary thyroid carcinoma. Acta Cytol. 2009;53(6):689–92.
Folpe AL, Lane KL, Paull G, Weiss SW. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas. Am J Surg Pathol. 2000;24(10):1353–60.
Meis-Kindblom JM, Kindblom LG, Enzinger FM. Sclerosing epithelioid fibrosarcoma. A variant of fibrosarcoma simulating carcinoma. Am J Surg Pathol. 1995;19(9):979–93.
Doyle LA, Moller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2011;35(5):733–41.
Panagopoulos I, Storlazzi CT, Fletcher CD, et al. The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer. 2004;40(3):218–28.
Matsuyama A, Hisaoka M, Shimajiri S, et al. Molecular detection of FUS-CREB3L2 fusion transcripts in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens. Am J Surg Pathol. 2006;30(9):1077–84.
Panagopoulos I, Moller E, Dahlen A, et al. Characterization of the native CREB3L2 transcription factor and the FUS/CREB3L2 chimera. Genes Chromosomes Cancer. 2007;46(2):181–91.
Lau PP, Lui PC, Lau GT, Yau DT, Cheung ET, Chan JK. EWSR1-CREB3L1 gene fusion: a novel alternative molecular aberration of low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2013;37(5):734–8.
Arbajian E, Puls F, Magnusson L, et al. Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma. Am J Surg Pathol. 2014;38(6):801–8.
Linos K, Bridge JA, Edgar MA. MUC 4-negative FUS-CREB3L2 rearranged low-grade fibromyxoid sarcoma. Histopathology. 2014;65(5):722–4.
Alatise OI, Oke OA, Olaofe OO, Omoniyi-Esan GO, Adesunkanmi AR. A huge low-grade fibromyxoid sarcoma of small bowel mesentery simulating hyper immune splenomegaly syndrome: a case report and review of literature. Afr Health Sci. 2013;13(3):736–40.
Evans HL. Low-grade fibromyxoid sarcoma. A report of 12 cases. Am J Surg Pathol. 1993;17(6):595–600.
Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20(12):1479–84.
Alfaro-Cervello C, Benavent Casanova O, Nieto G, Mares Diago FJ, Navarro S. Low-grade fibromyxoid sarcoma, an essential differential diagnosis in myxoid tumors with benign appearance. Rev Esp Patol. 2018;51(3):178–82.
Schneider N, Fisher C, Thway K. Ossifying fibromyxoid tumor: morphology, genetics, and differential diagnosis. Ann Diagn Pathol. 2016;20:52–8.
Yoshida A, Makise N, Wakai S, Kawai A, Hiraoka N. INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma. Mod Pathol. 2018;31(5):744–52.
Broehm CJ, Wu J, Gullapalli RR, Bocklage T. Extraskeletal myxoid chondrosarcoma with a t (9;16)(q22;p11.2) resulting in a NR4A3-FUS fusion. Cancer Genet. 2014;207(6):276–80.
Patterson JW, Tchernev G, Chokoeva AA, Wick MR. Sclerosing epithelioid fibrosarcoma. Wien Med Wochenschr. 2017;167(5–6):120–3.
Turc-Carel C, Dal Cin P, Limon J, et al. Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci U S A. 1987;84(7):1981–5.
Ud Din N, Ahmad Z, Zreik R, Horvai A, Folpe AL, Fritchie K. Abdominopelvic and retroperitoneal low-grade Fibromyxoid sarcoma: a Clinicopathologic study of 13 cases. Am J Clin Pathol. 2018;149(2):128–34.
Vallejo-Benitez A, Rodriguez-Zarco E, Carrasco SP, et al. Expression of dog1 in low-grade fibromyxoid sarcoma: a study of 19 cases and review of the literature. Ann Diagn Pathol. 2017;30:8–11.
Thway K, Ng W, Benson C, Chapman J, Fisher C. DOG1 expression in low-grade Fibromyxoid sarcoma: a study of 11 cases, with molecular characterization. Int J Surg Pathol. 2015;23(6):454–60.
Mei L, Smith SC, Faber AC, et al. Gastrointestinal stromal tumors: the GIST of precision medicine. Trends Cancer. 2018;4(1):74–91.
Conflict of interest
The authors disclose no conflicts.
No funding or support is associated with this study.
Ethics approval and consent to participate
This publication is approved by the IRB office of NYU Langone Medical Center.
Consent for publication
Consent from the patient is obtained.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Huang, J., Cohen, S. & Jour, G. Primary small intestine mesenteric low-grade fibromyxoid sarcoma with foci of atypical epithelioid whorls and diffuse DOG1 expression: a case report. Diagn Pathol 15, 23 (2020). https://doi.org/10.1186/s13000-019-0905-2
- Low grade fibromyxoid sarcoma
- Small bowel